Filing Analysis
Interpace Biosciences, Inc. has implemented a 1-for-5 reverse stock split effective August 27, 2026. The split aims to adjust the share price and was authorized by stockholders during the annual meeting held on August 20, 2026.
🚩 Red Flags
- Reverse stock split (often used to combat low share prices or avoid delisting).
- Trading on OTCID (indicates a move away from major exchanges or a shift in market tier).
📋 Key Facts
- Reverse split ratio: 1-for-5 (one share for every five shares outstanding).
- Effective date: August 27, 2026, at 12:01 a.m. ET.
- Ticker symbol change: Temporarily changing to 'IDXGD' on the OTCID quotation system for 20 trading days.
- CUSIP number change: New CUSIP is 46062X 402.
- Fractional shares: No fractional shares will be issued; instead, they will be rounded up to the nearest whole share.
- Impact: Adjusts per share exercise prices for outstanding stock options and shares eligible under the 2026 Incentive Stock Plan and 2026 Employee Stock Purchase Plan.
Interpace Biosciences, Inc. filed an amendment to its previous 8-K to formally disclose the stockholder approval and adoption of the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan (ESPP). These new plans replace the existing 2019 versions.
📋 Key Facts
- Stockholders approved the 2026 Benefit Plans at the annual meeting on August 20, 2026.
- The 2026 Equity Incentive Plan replaces the 2019 Equity Incentive Plan.
- The 2026 Employee Stock Purchase Plan (ESPP) replaces the 2019 ESPP.
- No further equity grants or purchases will be made under the 2019 plans as of the approval date.
Interpace Biosciences, Inc. held its 2026 annual meeting of stockholders where shareholders approved a proposal granting the Board discretionary authority to execute a reverse stock split. The split ratio is to be determined by the Board within one year, ranging from 1-for-2 to 1-for-10.
🚩 Red Flags
- Approval of reverse stock split authority (typically used to combat low share prices or meet exchange listing requirements).
📋 Key Facts
- Annual meeting held on August 20, 2026.
- Stockholders approved the authority for a reverse stock split with a ratio between 1-for-2 and 1-for-10.
- The exact ratio will be determined by the Board within one year of approval.
- The 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan were both approved.
- Five director nominees were elected to serve until the 2027 annual meeting.
- EisnerAmper, LLP was ratified as the independent accounting firm for fiscal year 2026.
Interpace Biosciences, Inc. filed an 8-K to announce its results of operations and financial condition for the quarter ended June 30, 2026.
📋 Key Facts
- Report date: August 10, 2026
- Filing date: August 12, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Interpace Biosciences, Inc. announced the full repayment of its outstanding term loan facility with BroadOak Capital Partners on December 3, 2025.
📋 Key Facts
- The company fully repaid its outstanding term loan facility with BroadOak Capital Partners.
- Repayment occurred prior to the facility's original maturity date.
- Announcement made via press release dated December 3, 2025.
Interpace Biosciences, Inc. filed an 8-K to announce its results of operations and financial condition for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Results of Operations).
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 12, 2025.
Interpace Biosciences, Inc. filed an 8-K to announce its results of operations and financial condition for the quarter ended June 30, 2025.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial performance.
Interpace Biosciences, Inc. filed an 8-K to announce its quarterly results of operations and financial condition for the period ending March 31, 2025.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial performance.
Interpace Biosciences is implementing a restructuring plan following the loss of Medicare reimbursement for its PancraGEN® test. The company expects to lose approximately one-third of its revenue due to this regulatory change and will undergo workforce reductions to offset these losses.
🚩 Red Flags
- Significant revenue risk: Expected loss of ~33% of total company revenue due to Medicare non-coverage.
- Regulatory/Reimbursement risk: Loss of a key diagnostic test reimbursement (LCD) is a material blow to the business model.
- Restructuring activity: Workforce reductions and severance costs indicate significant operational contraction.
📋 Key Facts
- Medicare Administrative Contractor Novitas Solutions issued an LCD ending reimbursement for PancraGEN® test, effective April 24, 2025.
- The company will stop accepting specimens for first-line fluid chemistry and PancraGEN® testing after May 2, 2025.
- Implementation of the Restructuring Plan is expected to be completed by the end of Q2 2025.
- Expected severance costs: $0.5 million to $0.6 million in Q2 2025 (additional to $0.2 million recorded in Q1).
- The loss of PancraGEN® is expected to reduce revenues by approximately one-third.
- Restructuring aims to reduce annualized cost of revenue and operating expenses by $12.5 million to $14.5 million.
Interpace Biosciences, Inc. has determined that its previously issued financial statements for fiscal year 2023 and various quarterly periods in 2023 and 2024 can no longer be relied upon due to necessary restatements of accrued royalty expenses. The company identified a material weakness in internal controls over financial reporting related to the assessment of these royalties.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02(a))
- Material weakness in internal control over financial reporting
- Significant error in liability accruals ($5.3M to $7.1M range)
- Restatement covers multiple fiscal years and quarters, indicating systemic accounting issues rather than a one-time error
📋 Key Facts
- Restatement affects FY 2023 Annual Report (10-K) and quarterly reports for periods ending March, June, and September in both 2023 and 2024.
- The error involves the overstatement of accrued royalties and total liabilities; specifically, liabilities were overstated by up to $7.1 million as of Sept 30, 2024.
- Management determined that royalty accruals were not required, leading to a reversal of expenses.
- The company identified a material weakness in internal control over financial reporting regarding the assessment of accrued royalty expenses as of Dec 31, 2023.
- Restatements are expected to have a positive impact on current liabilities, stockholders' equity (deficit), and net income.
- The restatement is not expected to result in material changes to revenues or consolidated statements of cash flows.
Interpace Biosciences is re-evaluating its previously announced restructuring plan following a CMS decision to delay the implementation of a Local Coverage Determination (LCD) that would have discontinued coverage for its PancraGEN® test. The delay shifts the effective date from February 23, 2025, to April 24, 2025.
🚩 Red Flags
- Significant regulatory uncertainty regarding CMS coverage for core product (PancraGEN®).
- Previous restructuring plan was triggered by the imminent loss of a major revenue stream/test coverage.
- High volatility in business operations due to shifting federal policy implementation dates.
📋 Key Facts
- CMS delayed implementation of Genetic Testing for Oncology LCD (L39365) from Feb 23, 2025, to April 24, 2025.
- The delay is intended to allow the incoming administration to review clinical evidence and patient care impacts.
- The company's previously announced restructuring plan (approved Jan 21, 2025) is currently being re-evaluated.
- PancraGEN® test was facing discontinuation due to non-coverage by Medicare Administrative Contractors.
Interpace Biosciences has entered into a Fourth Amendment to its Credit Agreement with BroadOak Fund V, L.P. and simultaneously approved a restructuring plan involving workforce reductions due to the loss of CMS coverage for PancraGEN®.
🚩 Red Flags
- Significant revenue risk: Expected loss of approximately one-third of total revenues due to CMS coverage changes.
- Debt restructuring/repayment pressure: Mandatory monthly principal payments and a full balloon payment required by Dec 31, 2025.
- Workforce reduction/Restructuring: Indicates significant operational distress or pivot in business model.
📋 Key Facts
- Entered into Fourth Amendment to Loan and Security Agreement on January 17, 2025.
- New repayment schedule: $500k principal + interest monthly from Feb 1, 2025, to June 1, 2025; accrued interest only July-Dec 2025; full payoff by Dec 31, 2025.
- One-time payment of 1% of the outstanding Term Loan Advance due Jan 17, 2025.
- Restructuring plan approved to address loss of CMS coverage for PancraGEN® product.
- Expected severance costs: $0.8 million to $1.0 million in Q1 2025.
- Anticipated annual cost savings (revenue/expense reduction): $12.5 million to $14.5 million, intended to offset a projected one-third revenue loss.
Interpace Biosciences announced that its subsidiary, Interpace Diagnostics, LLC, will cease offering the PancraGEN test due to a new Medicare Local Coverage Determination (LCD) establishing non-coverage for the test. This is significant as PancraGEN is primarily ordered for Medicare patients.
🚩 Red Flags
- Loss of a primary revenue driver (PancraGEN) due to regulatory/reimbursement changes.
- Significant impact on product portfolio as the test was 'primarily ordered for Medicare patients'.
- Immediate cessation of specimen acceptance by February 7, 2025.
📋 Key Facts
- CMS issued a final LCD (L39365) regarding Genetic Testing for Oncology.
- The new LCD establishes non-coverage for the Company's PancraGEN test.
- PancraGEN is used to assess pancreatic cyst cancer risk.
- Specimens for first-line fluid chemistry and PancraGEN testing will not be accepted after February 7, 2025.
- The company will no longer offer the PancraGEN test because it is primarily ordered for Medicare patients.
Interpace Biosciences, Inc. held its 2024 annual meeting of stockholders on November 12, 2024. The primary outcome was the ratification of EisnerAmper, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual meeting held on November 12, 2024.
- Stockholders ratified the appointment of EisnerAmper, LLP as independent auditors for FY2024.
- Voting results: 10,973,903 For; 13,711 Against; 2,680 Abstain.
Interpace Biosciences, Inc. filed an 8-K to announce its third quarter 2024 financial results for the period ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly results (Item 2.02).
- Results cover the third quarter ended September 30, 2024.
- The press release containing the detailed financial data was issued on November 4, 2024.
Interpace Biosciences completed an exchange of all outstanding Series B Preferred Stock for newly created Series C Preferred Stock. This restructuring significantly reduces investor liquidation preferences and removes several restrictive protective provisions, but results in a massive potential dilution to common shareholders.
🚩 Red Flags
- Massive potential dilution: Conversion of Series C could result in over 23 million new common shares being issued.
- No cash inflow: The restructuring was a non-cash exchange that does not provide immediate working capital to the company.
- Significant change in capital structure via unregistered sale of equity securities.
📋 Key Facts
- Exchanged 47,000 shares of Series B Preferred Stock for 47,000 shares of Series C Preferred Stock.
- Series C Conversion Price is $2.02 per share (based on Oct 10, 2024 closing price).
- The aggregate number of Common Stock shares issuable upon conversion of all Series C shares is 23,267,326 shares.
- Series C Preferred Stock has no liquidation preference over Common Stock and no director designation rights.
- Termination of a prior Support Agreement with 1315 Capital as part of the exchange.
- The transaction resulted in zero cash proceeds for the Company.
Interpace Biosciences, Inc. filed an 8-K to announce its results of operations and financial condition for the second quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 1, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing serves to furnish quarterly financial results via a press release (Exhibit 99.1).
Interpace Biosciences, Inc. filed an 8-K to announce its results of operations and financial condition for the quarter ended March 31, 2024.
📋 Key Facts
- The filing relates to the quarterly earnings release for the period ending March 31, 2024.
- The report was filed on May 9, 2024.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Interpace Biosciences, Inc. issued a press release announcing preliminary results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 7, 2024
- Reporting period: Q4 and Fiscal Year ended December 31, 2023
- The filing is a standard announcement of preliminary financial results via Exhibit 99.1.